Ozaki, Hajime
Suga, Hidetaka
Sakakibara, Mayu
Soen, Mika
Miyake, Natsuki
Miwata, Tsutomu
Taga, Shiori
Nagai, Takashi
Kano, Mayuko
Mitsumoto, Kazuki
Miyata, Takashi
Kobayashi, Tomoko
Sugiyama, Mariko
Onoue, Takeshi
Takagi, Hiroshi
Hagiwara, Daisuke
Iwama, Shintaro
Banno, Ryoichi
Iguchi, Genzo
Takahashi, Yutaka
Muguruma, Keiko
Inoue, Haruhisa
Arima, Hiroshi
Funding for this research was provided by:
the Project for Technological Development of the Research Center Network for Realization of Regenerative Medicine (RCNRRM), funded by AMED (JP17bm0404018, JP20bm0404036)
the Acceleration Program for Intractable Diseases Research Utilizing Disease-Specific iPS Cells of RCNRRM funded by AMED (JP19bm0804011)
Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (JP17K09878, JP20K08859)
Nagoya University Hospital Funding for Clinical Research (71004136)
Fusion Oriented Research for disruptive Science and Technology (FOREST) by Japan Science and Technology Agency
the Hori Sciences and Arts Foundation
the Toyoaki Scholarship Foundation
the Daiko Foundation
the Nitto Foundation
the Suzuken Memorial Foundation
the Program for Intractable Disease Research Utilizing Disease-Specific iPS Cells from the Japan Science and Technology (JST) agency and the Japan Agency for Medical Research and Development (JP15bm0404009, JP16bm0609002)
Article History
Received: 24 December 2021
Accepted: 14 October 2022
First Online: 17 October 2022
Competing interests
: The authors declare the following competing interests: Shiori Taga is an employee of Sumitomo Dainippon Pharma Co., Ltd. The other authors declare no competing interests.